Health ❯ Healthcare ❯ Oncology ❯ Breast Cancer

Triple-Negative Breast Cancer

Sacituzumab Govitecan Gains First-Line Ground in TNBC, Falls Short in Early HR+/HER2− Use

SABCS presentations underscore subtype‑specific use requiring careful treatment sequencing.

ASCENT-03 Finds Sacituzumab Govitecan Extends PFS Over Chemotherapy in First-Line PD-L1–Negative TNBC

Datroway Extends Survival Over Chemotherapy in First-Line TNBC Ineligible for Immunotherapy

Paclitaxel Reengineered Into Self-Assembling Nanovesicle Shows Strong Preclinical Gains

Everolimus Plus Carboplatin Delays Progression in Advanced Triple-Negative Breast Cancer, Phase 2 Study Shows